Trial Profile
A Study Comparing the Benefits and Risks of Eltrombopag and Romiplostim in Patients with Immune Thrombocytopenia (ITP) in the Real World Setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2017
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary) ; Romiplostim
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Therapeutic Use
- 29 Dec 2017 New trial record
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.